June 2024

Marketing Material

Bionics

With a growing imbalance between healthcare demand and workforce, Bionics - the cutting-edge of Medtech - expands its addressable market much faster than global GDP. Innovation makes for advanced care, longer lifespan, better wellness, and lower total costs. Pure-players revolutionizing healthcare through tech have an opportunity to grow aggressively their revenues and, more importantly, their earnings over the next several years.

The strategy’s investment objective is to achieve long-term capital appreciation by allocating investments to such companies depending on their growth rate and quality.

Main Features
Asset Class Equity
Legal Structure Actively Managed Certificate
Investment Index Long
Launch date 25-Jun-19
Currency USD
Type of Return Total return
Ticker JMLNARBN
isin XS1668108415
Issuer JP Morgan
Issue Price 150
Last Price 156.50
Sharpe Ratio 0.03
Correlation 0.66
Beta 1.34
Reference Index MSCI World Health Care Net (USD)
Liquidity Daily
# Holdings 25
Management Fees 1.30%
Issuer Fees 0.20%
Performance Fees 15.00%
ALL TIME HIGH ALL TIME LOW
PRICE: 269.8 PRICE: 114.0
DATE: 12-Feb-21 DATE: 30-Oct-23

Bionics

With a growing imbalance between healthcare demand and workforce, Bionics - the cutting-edge of Medtech - expands its addressable market much faster than global GDP. Innovation makes for advanced care, longer lifespan, better wellness, and lower total costs. Pure-players revolutionizing healthcare through tech have an opportunity to grow aggressively their revenues and, more importantly, their earnings over the next several years.

The strategy’s investment objective is to achieve long-term capital appreciation by allocating investments to such companies depending on their growth rate and quality.

Monthly Returns $

(Net of fees)

* Estimated
* Actual

JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC ANNUAL
2024 -3.3% 0.0% 3.9% -1.1% 5.0% -1.7% 2.6%
2023 3.0% -1.9% 1.1% 6.1% -0.7% 6.6% -2.2% -16.3% -11.4% -14.0% 18.3% 10.8% -6.1%
2022 -17.2% 3.3% 4.4% -18.2% -7.6% -3.1% 12.1% 7.5% -6.6% 9.6% 4.3% -6.7% -21.4%
2021 4.5% -4.4% -3.2% 8.4% -7.1% 9.0% -5.9% 4.8% -7.3% 5.0% -11.9% -2.1% -12.0%
2020 -0.2% -5.6% -7.1% 15.4% 7.8% -0.1% 10.4% 3.6% 3.3% -3.8% 10.5% 6.3% 45.3%
2019 1.1% -0.3% -0.8% -0.0% 1.1% 7.1% -0.3% 7.8%
Industry Exposure

Top 3 Holdings
  • TRANSMEDICS GROUP
  • INSULET
  • DEXCOM
Top 3 Contributors
  • TRANSMEDICS GROUP
  • INSULET
  • INTUITIVE SURGICAL
Worst 3 Contributors
  • INSPIRE MEDICAL
  • NOVOCURE
  • PACIFIC BIOSCIENCES
Geographical
Breakdown
Currency
Exposure
Asset
Allocation
Equity Market Cap
Distribution
Equity
Liquidity*

*On average 3 Months daily trading volume

Risk
Scale

6


The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back

Industry Exposure